ROIV vs. BNTX, TEVA, BGNE, SMMT, MRNA, GMAB, VTRS, ITCI, CTLT, and RDY
Should you be buying Roivant Sciences stock or one of its competitors? The main competitors of Roivant Sciences include BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Summit Therapeutics (SMMT), Moderna (MRNA), Genmab A/S (GMAB), Viatris (VTRS), Intra-Cellular Therapies (ITCI), Catalent (CTLT), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry.
Roivant Sciences vs.
Roivant Sciences (NASDAQ:ROIV) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends, community ranking and analyst recommendations.
BioNTech received 89 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 77.27% of users gave Roivant Sciences an outperform vote while only 46.05% of users gave BioNTech an outperform vote.
64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 7.9% of Roivant Sciences shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Roivant Sciences has a net margin of 3,827.42% compared to BioNTech's net margin of -15.16%. BioNTech's return on equity of -2.35% beat Roivant Sciences' return on equity.
Roivant Sciences presently has a consensus target price of $17.93, indicating a potential upside of 60.87%. BioNTech has a consensus target price of $142.72, indicating a potential upside of 15.15%. Given Roivant Sciences' higher probable upside, equities research analysts clearly believe Roivant Sciences is more favorable than BioNTech.
In the previous week, BioNTech had 1 more articles in the media than Roivant Sciences. MarketBeat recorded 9 mentions for BioNTech and 8 mentions for Roivant Sciences. BioNTech's average media sentiment score of 0.97 beat Roivant Sciences' score of 0.83 indicating that BioNTech is being referred to more favorably in the news media.
Roivant Sciences has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, BioNTech has a beta of 0.18, meaning that its share price is 82% less volatile than the S&P 500.
Roivant Sciences has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
BioNTech beats Roivant Sciences on 10 of the 19 factors compared between the two stocks.
Get Roivant Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Roivant Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:ROIV) was last updated on 1/28/2025 by MarketBeat.com Staff
